Akebia Therapeutics (AKBA) Other Non-Current Assets (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Other Non-Current Assets data on file, last reported at $56.6 million in Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $56.6 million, up 47.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $56.6 million (up 47.55% YoY), and the FY2025 annual result was $59.7 million, up 59.67% from the prior year.
• Other Non-Current Assets declined to $56.6 million in Q1 2026 per AKBA's latest filing, from $59.7 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $59.7 million in Q4 2025 and troughed at $3.3 million in Q2 2023.
• A 5-year average of $27.3 million and a median of $27.1 million in 2024 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2023 and 2024: Other Non-Current Assets tumbled 90.42% in 2023, then surged 602.59% in 2024.
• A 5-year view of Other Non-Current Assets shows it stood at $5.4 million in 2022, then surged by 131.25% to $12.4 million in 2023, then surged by 200.87% to $37.4 million in 2024, then soared by 59.67% to $59.7 million in 2025, then slipped by 5.21% to $56.6 million in 2026.
• Business Quant data shows AKBA's Other Non-Current Assets at $56.6 million in Q1 2026, $59.7 million in Q4 2025, and $40.5 million in Q3 2025.